Graphite Bio enters retention agreements with senior management amid strategic review

LENZ Therapeutics, Inc.

Retention agreements cover CEO, CFO, and other senior executives, providing lump sum cash equal to 50% of annual base salary upon qualifying termination or Feb 22, 2024.
50% acceleration of unvested equity awards granted in 2023 on qualifying termination after June 30, 2023.
Stock option exercise period extended to 12 months post-termination or original expiry.
Strategic alternatives process is ongoing; retention agreements designed to retain key talent.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.